Prevalence of human herpesvirus 8 (HHV8) and hepatitis C virus (HCV) in a rural community with high risk for blood borne
infections in central China by Zhang, Tiejun et al.
University of Nebraska - Lincoln
DigitalCommons@University of Nebraska - Lincoln
Virology Papers Virology, Nebraska Center for
2011
Prevalence of human herpesvirus 8 (HHV8) and
hepatitis C virus (HCV) in a rural community with
high risk for blood borne infections in central
China
Tiejun Zhang
Fudan University
Na He
Fudan University
Yingying Ding
Fudan University
Kay L. Crabtree
University of Nebraska-Lincoln, acrabtree2@unl.edu
Veenu Minhas
University of Nebraska-Lincoln, veenu.minhas@unmc.edu
See next page for additional authors
Follow this and additional works at: http://digitalcommons.unl.edu/virologypub
Part of the Biological Phenomena, Cell Phenomena, and Immunity Commons, Cell and
Developmental Biology Commons, Genetics and Genomics Commons, Infectious Disease
Commons, Medical Immunology Commons, Medical Pathology Commons, and the Virology
Commons
This Article is brought to you for free and open access by the Virology, Nebraska Center for at DigitalCommons@University of Nebraska - Lincoln. It
has been accepted for inclusion in Virology Papers by an authorized administrator of DigitalCommons@University of Nebraska - Lincoln.
Zhang, Tiejun; He, Na; Ding, Yingying; Crabtree, Kay L.; Minhas, Veenu; and Wood, Charles, "Prevalence of human herpesvirus 8
(HHV8) and hepatitis C virus (HCV) in a rural community with high risk for blood borne infections in central China" (2011).
Virology Papers. 350.
http://digitalcommons.unl.edu/virologypub/350
Authors
Tiejun Zhang, Na He, Yingying Ding, Kay L. Crabtree, Veenu Minhas, and Charles Wood
This article is available at DigitalCommons@University of Nebraska - Lincoln: http://digitalcommons.unl.edu/virologypub/350
Prevalence of human herpesvirus 8 (HHV8) and hepatitis C virus
(HCV) in a rural community with high risk for blood borne
infections in central China
Tiejun Zhang1,2, Na He1, Yingying Ding1, Kay Crabtree2, Veenu Minhas2, and Charles
Wood2
1Department of Epidemiology, School of Public Health, Fudan University, Shanghai, China and
Key Laboratory of Public Health Safety (Fudan University), Ministry of Education, China
2Nebraska Center of Virology and the School of Biological Sciences, University of Nebraska-
Lincoln, USA
Abstract
Former illegal blood donation in the past decade has caused HIV outbreaks in some rural areas in
China. Other HIV associated virus infections, such as human herpesvirus 8 (HHV8) in such areas
are still not well defined. In order to explore HHV8 and HCV seroprevalence and potential risk
factors in such areas, a cross-sectional study with 305 HIV positive and 315 HIV negative subjects
recruited from a rural county in Shanxi province was conducted, where illegal blood collection
was reported. Interview questionnaires and serum testing were carried out with these participants.
HCV and HHV8 seroprevalence were found to be higher in HIV positive than negative group
(76.4% vs. 2.5%; 15.4% vs. 4.8% respectively), while the difference in HBV seroprevalence was
not significant. Co-infection with HCV and HHV8 was also more prevalent in the HIV positive
group. HIV status (odds ratio [OR], 2.71; 95% confidence interval [CI], 1.16–6.30) and HBV
status (OR, 2.56; 95%CI: 1.14–5.75) were independently associated with HHV8 infection. HIV
status (OR, 23.03; 95%CI: 9.95–53.27) and blood/plasma selling history (OR, 14.57; 95%CI:
7.49–28.23) were strongly associated with HCV infection. These findings demonstrate that both
HHV8 and HCV infections are prevalent in this community. HIV infection is an important risk
factor for both HHV8 and HCV infection. HBV infection is associated with HHV8 infection but
not with HCV infection. It is possible that HHV8 and HBV, but not HCV, may have similar mode
of transmission in this population.
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INTRODUCTION
Human herpesvirus 8 (HHV8), also known as Kaposi’s sarcoma-associated herpesvirus
(KSHV), a member of the gamma herpesvirus family, has consistently been found to be
associated with all forms of Kaposi’s sarcoma (KS). It is also associated with other
lymphoproliferative diseases such as primary effusion B-cell lymphomas (PELs) and
multicentric Castleman's disease (MCD) [1]. HHV8 infection is not ubiquitous and the
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prevalence varies in different populations but is commonly found in HIV positive
individuals. HHV8 seroprevalence is generally low to moderate in western countries,
ranging from 3% to 23% [2–4]. However, in sub-Saharan Africa, seroprevalence can be as
high as 50% in the general population, and is even higher in the HIV positive population [5–
7]. Data from Asian countries suggests that HHV8 seroprevalence is generally low [8].
Several epidemiological studies have been conducted to study the route of transmission and
risk factors involved in acquiring HHV-8 infection [9–11]. While salivary transmission has
emerged to be one of the major routes of transmission, a recent study conducted in Uganda
has clearly demonstrated that transmission via blood transfusion can occur, albeit
inefficiently [12].
In addition to HHV8, unmonitored blood transfusion may also increase the risk for acquiring
hepatotropic viral infections, such as hepatitis C virus (HCV) and HBV. These viruses have
been known to share similar routes of transmission and risk factors with HIV. It has also
been reported that HCV coinfection is very common among HIV positive populations
[13,14].
During early 1990s, illegal plasma and blood collection by commercial establishments was
common in rural areas of central China, mainly as a mean for rural farmers to augment their
household income [15]. Practices such as pooling of blood and re-infusion of red blood cells
from donors with compatible blood types, exposed the blood donors to various blood borne
pathogens including HIV. This practice had led to an outbreak of HIV in rural central China.
Since the first outbreak of HCV infection among plasma donors in China in 1991, studies
have shown a high seroprevalence of HCV in the illegal blood donor population [13,16]. In
contrast, very little is known about HHV8 epidemiology in China, especially in this unique
high risk population. A few studies on HHV8 prevalence in mainland China and in Xinjiang
Uygur autonomous region in Northwestern China, which is an endemic area for KS, have
been reported [17,18]. No seroprevalence studies of HHV8 have been conducted in areas of
central China where a large number of illegal commercial blood/plasma donors reside, even
though high prevalence of HCV and HIV has been observed in this area. The prevalence of
HHV8 in this population and its correlation to HIV, HBV and HCV infection is not known.
Therefore, we conducted a cross-sectional epidemiological study to ascertain the
seroprevalence of HHV8 and HCV among HIV infected patients and compared them to HIV
negative individuals in a rural area in Shanxi province of Central China. To our knowledge,
this is the first study to document HHV8 seroprevalence in this population. These findings
will contribute to an enhanced awareness of HHV8 infection among these former blood
donors.
MATERIALS AND METHODS
Study cohort and sample collection
The present study was conducted in Yun-cheng city, a rural prefecture area of Shanxi
province in Central China, a community that harbors a large number of former illegal blood
donors. The first case of HIV in a plasma donor for commercial gain from Yun-cheng city
was reported in 1996. Since then 626 HIV/AIDS cases were reported by the end of 2004. Of
these, 246 cases had died, 43 were untraceable.
A total of 620 subjects were included in the present study and all samples were collected in
late 2004 through early 2005 for an observational study about the quality of life in this
population. All samples were divided into two groups: a) HIV+ Group: All HIV-infected
adults were recruited from the local clinic which offered free antiretroviral treatment
program, as part of the national anti-HIV/AIDS campaign. Only adults participated in this
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study and 305 out of 326 cases (93.6%) gave consent. The rest 21 patients were unreachable,
refused to be interviewed or provide blood sample. b) HIV− Group: This group included
315 HIV uninfected individuals who were randomly selected from a local community–based
adult HIV screening program from a village in the study area.
Venous blood was drawn from each study subject, coded with a unique identification
number and then transferred to the laboratory within 4 hours after collection. Plasma was
aliquoted and stored at −70 °C. All assays were performed blindly and this study was
approved by the Institutional Review Board of Fudan University, Shanghai, China.
Serological testing
a) HIV—All samples were screened with commercial enzyme-linked immunosorbent assay
(ELISA; Abbott Laboratories) for HIV antibodies according to the manufacturers’ protocol.
Samples tested positive by ELISA were confirmed by Western blotting.
b) HCV & HBV—ELISA for HBV surface antigen (HBsAg) and anti-HCV
immunoglobulin G (IgG) antibodies was conducted to determine HBV and HCV infection
status, according to the manufacturers’ protocol (Wantai Biomedical Co. Ltd, Beijing,
China). All samples were assayed in duplicate.
c) HHV8—Plasma samples were tested by monoclonal antibody-enhanced
immunofluoresence assay (IFA) as reported previously [19]. Briefly, two HHV8 serology
tests were used. First, BC-3 cells, HHV8 positive and Epstein-Barr virus (EBV) negative B
cell line (American Type Culture Collection, Manassas, VA.), stimulated by tetradecanoyl
phorbol acetate (TPA) were fixed, permeabilized and used for monoclonal-enhanced
immunofluorescence assay. Second, Spodoptera frugiperda clone 9 (Sf9) expressing three
viral recombinant proteins, ORF73, ORF65 and K8.1, were used for testing. The procedure
was similar to the BC-3 IFA. A sample was considered HHV-8-seropositive only if it was
positive at a standard serum dilution of 1:40 utilizing both BC-3 and Sf9 assays. Each slide
was read independently by two experienced laboratory workers.
Statistical analysis
Original questionnaire data and laboratory results were entered and managed with EpiData
3.0, and then transferred to SPSS v11.5 (Chicago, USA) for further analysis. Pearson Chi-
square test and univariate logistic regression analyses were performed to explore correlates
of HCV or HHV8 seropositivity. Multiple logistic regression analyses were conducted to
identify risk factors for HCV or HHV8 prevalence after adjusting for potential confounders.
Odds ratios (OR) with 95% confidence intervals (95% CI) were generated to determine
whether a variable was independently associated with HCV or HHV8 prevalence. All p-
values ≤0.05 were considered statistically significant. Mann-Whitney U test was used to
assess the difference of geometric mean titers (GMTs) of HHV8 between the HIV+ and the
HIV− groups. All statistical analyses were carried out using the SPSS software v11.5.
Graphpad prism 5.0 (La Jolla, CA, USA) was used to construct figures.
RESULTS
Study cohort and characteristics
We enrolled 620 study participants (median age 43.0 years) from Yun-cheng city for the
purposes of this study. The Han ethnic group is the major ethnic group in this province. The
differences in ethnicity, age group, marital status, education and profession between the two
groups were not significant. The HIV group was more likely to have multiple sex partners
and individuals who had never used a condom. Seventy three percent of the HIV positive
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people sold blood/plasma at least once, 16.1% had a history of receiving blood transfusions,
and 11.1% had history of surgery. The major demographic characteristics of all participants
(305 HIV positive and 315 HIV negative subjects) are summarized in Table 1.
HHV8 serology and associated risks factors
We conducted logistic regression analysis for risk factors associated with HHV-8
seroprevalence in this population. HHV8 seroprevalence was significantly higher in the HIV
positive than negative individuals (15.4% vs. 4.8%, respectively; P < 0.001). The univariate
analysis showed that HIV infection, HBV infection and a history of blood/plasma donation
were associated with HHV8 infection. Multiple logistic regression analysis indicated that
HIV and HBV infection were independently associated with HHV8 infection (OR 2.71, 95%
CI: 1.16–6.30 and OR 2.56, 95% CI: 1.14–5.75, respectively) (Table 2).
HHV8 Antibody titer distribution
We also wanted to determine whether the geometric mean titer (GMT) of HHV8 antibodies
differed between HIV+ and HIV− groups. Therefore, plasma from all HHV8 seropositive
subjects was serially diluted and tested for IgG anti-HHV8 antibody titer. As shown in
Figure 1, the GMT of HHV8 antibodies was 417.3 (95% CI: 319.5–545.1) for HIV positive
group (n=47) and 403.2 (95% CI: 294.7–551.6) for HIV negative group (n=15). We did not
observe any significant difference between the GMT of HHV8 antibodies between HIV
infected and uninfected group (Mann-Whitney U=357.5, P=0.782).
HCV serology and associated risk factors
HCV seroprevalence was significantly higher in the HIV positive than negative group
(74.4% vs. 2.5%, respectively; P < 0.001). In the univariate analysis, gender, condom usage,
HIV status, history of selling blood/plasma and history of surgery were found to associate
with HCV infection. Multivariate analysis indicated that subjects who were HIV positive
(OR 23.03; 95%CI 9.95–53.27) or those who had a history of selling blood/plasma (OR
14.57; 95%CI 7.49–28.23) were more likely to be HCV seropositive than those who were
HIV negative or had no history of selling blood/plasma (Table 3).
Coinfection of HBV, HCV and HHV8
The overall seroprevalence of HBV, HCV and HHV8 among the study subjects was 7.3%
(45/620), 38.9% (241/620) and 10.0% (62/620), respectively. The seroprevalence of HBV,
HCV and HHV8 was 7.5% (23/305), 76.4% (233/305) and 15.4% (47/305), respectively in
the HIV positive group, and 7.0% (22/315), 2.5% (8/315) and 4.8% (15/315), respectively in
the HIV negative group. Both HIV-infected and uninfected groups had no significant
difference in prevalence of HBV (P=0.789) but had significant difference in prevalence of
both HCV (P < 0.001) and HHV8 (P < 0.001). As shown in Table 4, 54 (17.7%) HIV-
infected individuals were not coinfected with HBV, HCV or HHV8. However, 202 (66.2%)
were coinfected with either one of the three viruses; 46 (15.1%) were coinfected with two
viruses, and 3 (1.0%) were coinfected with all three viruses. Among the 202 HIV-infected
individuals who were coinfected with only one of the above three viruses, 187 (92.6%) were
coinfected with HCV (Table 4). Among the 46 HIV positive individuals with coinfections of
two out of three viruses, 31 (67.4%) were coinfected with HCV and HHV8. For HIV-
uninfected individuals, the majority (87.3%) were negative for all three viruses. Thirty-five
(11.1% of 315) were coinfected with only one other virus, of which 51.4% were HBV-
infected. Five (1.6%) were coinfected with two other viruses (HBV, HCV and/or HHV8),
and none with all three viruses (Table 4).
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DISCUSSION
Given the continuing spreading of the HIV/AIDS epidemic in China, HHV8, an important
opportunistic infection could become a major public health concern in China. However,
little information is available for the prevalence and transmission patterns of HHV8 among
the Chinese population, which can be of great importance to HHV8 prevention and control
in China and to HIV/AIDS care in particular. Therefore, studies to understand the modes of
HHV8 transmission and risk factors for HHV8 acquisition in China are required.
The results from this study demonstrated a higher HHV8 seroprevalence (15.4%) in HIV
positive group as compared to the HIV negative group (4.8%), which is consistent with
other serological studies on epidemiology of HHV8 infection in Shandong area, a
neighboring province in China [20]. HHV8 prevalence varies considerably in different
regions of the country. It is reported to be 19.3% to 46.6% in the general population of
Xinjiang, but only between 7.3% to 16.1% in other provinces in China [17,18,20,21]. In
support of other studies conducted in China, we also find that HHV8 infection is not
ubiquitous in China. Compared with results from the Xinjiang area, our subjects have
relatively low HHV8 prevalence. The reason for these differences may due to ethnicity,
socioeconomic status, environmental characteristics and hygiene practices. Previous data
have shown that both the ethnic and socioeconomic factors can influence HHV8 infection,
even in the Han population in Xinjiang, which was regarded as a low risk group throughout
China, although the HHV8 prevalence in the same ethnic group is higher than in other parts
of China [17]. Interestingly, in our study, the HIV positive group was found to have a
slightly higher anti-HHV8 antibody titer than the negative group, although the difference is
not statistically significant.
As expected, we observed a very high level of coinfection with HCV in the HIV positive
group (76.4%) and a much lower HCV prevalence in the HIV negative group (2.5%), which
reflects the infection rate of general population in the rest of China. Since both HCV and
HIV are transmitted via blood, with HCV being more infectious than HIV, it is not
surprising that high HCV coinfection rate was detected in this study. Several studies on the
HCV coinfection in former blood donors from other areas in China have shown similar
results, demonstrating that the HCV prevalence can be as high as 78.6% to 86.3% among
HIV positive subjects [13,22,23]. Our results further confirm that HCV infection is primarily
blood-borne and is of public health importance to antiretroviral therapy (ART) in areas with
illegal plasma/blood donors.
The current study results suggest that HIV infection was positively associated with both
HHV8 and HCV infections. Furthermore, there is an association between HHV8 and HBV,
but not between HHV8 and HCV coinfections. It is possible that factors associated with
HBV transmission, such as close familial contact and sharing hygiene equipment are also
potentially associated with HHV8 transmission. In fact, association between HHV8 and
HBV infections has been reported in previous studies [12,24]. Since the HIV transmission
route and blood/plasma selling history were independently associated with HCV but not
with HHV8 and HBV, it is likely that HHV8 transmission route in this population is not via
blood and is different from HCV. The association between HIV and HHV8 co-infection
could be due to immunosuppression which rendered HIV infected individuals more
susceptible to HHV8 infection. A previous study on HHV8 transmission has shown that
transmission of HHV8 via blood is inefficient [25]. In fact passive transfer of HHV8
antibody was even suggested to have a protective effect in HHV8 transmission [26]. In our
study no association between sexual behavior, including multiple sex patterns, condom use
and HHV8 positive status was observed. This is also consistent with several previous studies
demonstrating that heterosexual transmission of HHV8 is rare [27,28]. Together these
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findings support the hypothesis that common routes of transmission are rarely shared by
HCV and HHV8 infections in this area, which deserve further intensive research.
In conclusion, both HHV8 and HCV infections are prevalent in this former illegal blood
donating community, with HIV acting as an important factor for their coinfection. Our data
demonstrates that HBV infection is associated with HHV8 infection but not with HCV
infection. HHV8 and HBV, but not HCV, may have similar mode of transmission in this
population. A number of studies have shown that HHV8 can be detected and potentially be
transmitted via saliva contact [29,30], it is possible that the saliva might play an important
role in transmission in this study population. We are unable to delineate this route as saliva
samples were not collected as a part of this study. Further, prospective studies on HHV8
seroprevalence and more extensive risk factor analysis, such as living arrangement, hygiene
conditions and food sharing practices are needed to explore the epidemiology of HHV8
infection in this population.
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Figure 1.
GMT of HHV8 antibodies in seropositive participants in the HIV positive and negative
groups.
*Antibody titers were determined by IFA based on BC3 slides. GMT for both groups were
calculated and compared. (Mann-Whitney U=357.5, P=0.782)
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Table 1
Characteristics of study participants.
HIV + Group HIV− Group Total
Gender (P=0.002)
   Male 165 (54.1%) 132 (41.9%) 297 (47.9%)
   Female 140 (45.9%) 183 (58.1%) 323 (52.1%)
Ethnicity (P=0.078)
   Han 302 (99.0%) 315 (100.0%) 617 (99.5%)
   Others 3 (0.9%) 0 (0%) 3 (0.5%)
Age group (P=0.029)
   19–29 10 (3.3%) 18 (5.7%) 28 (4.5%)
   30–49 224 (73.4%) 201 (63.8%) 425 (68.6%)
   50+ 71 (23.3%) 96 (30.5%) 167 (26.9%)
Marital status (P=0.720)
   Married 292 (95.7%) 302 (95.9%) 594 (95.8%)
   Single 4 (1.3%) 6 (1.9%) 10 (1.6%)
   Divorced/Widowed 9 (3.0%) 7 (2.2%) 16 (2.6%)
Education (P=0.019)
   Illiterate 26 (8.5%) 14 (4.4%) 40 (6.5%)
   Primary school 109 (35.7%) 111 (35.3%) 220 (35.5%)
   Middle school 154 (50.5%) 156 (49.5%) 310 (50.0%)
   High school or higher 16 (5.2%) 34 (10.8%) 50 (8.1%)
Farmer (P=0.019)
   Yes 290 (95.1%) 284 (90.2%) 574 (92.6%)
   No 15 (5.0%) 31 (9.1%) 46 (7.4%)
Multiple sex partners (P=0.012)
   Yes 16 (5.2%) 5 (1.6%) 21 (3.4%)
   No 289 (94.8%) 310 (98.4%) 599 (96.6%)
Ever used condoms (P<0.001)
   Yes 256 (83.9%) 290 (93.8%) 546 (88.9%)
   No 49 (16.1%) 19 (6.0%) 68 (11.1%)
Ever had blood transfusion (P<0.001)
   Yes 49 (16.1%) 16 (5.1%) 65 (10.5%)
   No 256 (83.9%) 299 (94.9%) 555 (89.5%)
Ever donated blood/plasma (P<0.001)
   Yes 223 (73.1%) 0 (0%) 223 (35.9%)
   No 82 (26.9%) 315 (100%) 397 (64.1%)
Ever had a surgery (P<0.001)
   Yes 34 (11.1%) 12 (3.8%) 46 (7.5%)
   No 271 (88.9%) 303 (96.2%) 574 (92.5%)
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Table 4
Summary of infection by HBV, HCV and HHV8 in HIV positive and negative groups
HIV+ Group (N=305) HIV− Group (N=315)
Co-infected with No. Prevalence
(%)
No. Prevalence
(%)
None 54* 17.7 275 87.3
Single virus only
  HBV 5* 1.6 18 5.7
  HCV 187* 61.3 6 1.9
  HHV8 10* 3.3 11 3.5
Dual viruses
  HBV+HCV 12* 3.9 1 0.3
  HBV+HHV8 3* 1.0 3 1.0
  HCV+HHV8 31* 10.2 1 0.3
Triple viruses
  HBV+HCV+HHV8 3* 1.0 0 0
*
These infections are HHV8, HCV or HBV plus HIV
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